DCGI Permits Convalescent Plasma Therapy For COVID-19 Patients

The Drug Controller General of India has permitted the ICMR for initiating a clinical trial of convalescent plasma therapy on COVID-19 patients. 

In this therapy, blood is drawn from a person who has recovered from the disease and the serum is separated and screened for virus-neutralising antibodies. These antibodies are then inserted in infected individuals to build their immunity.